<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Latest technologies from HSC Innovations</title><link>http://hscinnovations.technologypublisher.com</link><description>Be the first to know about the latest inventions and technologies available from HSC Innovations</description><language>en-US</language><pubDate>Mon, 04 May 2026 15:44:58 GMT</pubDate><lastBuildDate>Tue, 30 Sep 2014 05:08:39 GMT</lastBuildDate><docs>http://blogs.law.harvard.edu/tech/rss</docs><webMaster>enquiries@innovations.hscni.net</webMaster><copyright>Copyright 2026, HSC Innovations</copyright><item><title>Group B Streptococcus - Rapid Molecular Assay</title><caseId>EXT-14-021</caseId><link>http://hscinnovations.technologypublisher.com/technology/16010</link><description><![CDATA[GROUP B STREPTOCOCCUS - RAPID MOLECULAR ASSAY
&nbsp;
CONTEXT
The Problem
Group B streptococcus (GBS) is one of the most important infectious causes of neonatal morbidity and mortality in developed countries, causing meningitis, pneumonia and septicaemia in newborn babies and their mothers. Vaginal colonisation by GBS is reported in up to 27% of women, and can lead to intrapartum infection of neonates. Early-onset disease (0-7 days) presents as pneumonia and/or bacteraemia, with case fatality rates of up to 29% reported. Late onset disease (7-90 days) presents as bacterial meningitis, with case...]]></description><pubDate>Tue, 30 Sep 2014 05:08:39 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/16010</guid></item><item><title>Use of Riboflavin for the Targeted Treatment of Resistant Hypertension in a Genetically Predisposed Group</title><caseId>EXT-11-020</caseId><link>http://hscinnovations.technologypublisher.com/technology/6437</link><description>Background
Hypertension is the most common risk which attributes 
to death worldwide and is estimated to be responsible for 62% of stroke and 49% 
of coronary vascular disease (CVD) cases. It is estimated that up to 60% (1.56 
bn) of the world’s adult population will suffer from hypertension related 
problems by 2025.
Despite the availability of effective 
antihypertensive drugs, hypertension remains uncontrolled in many patients and 
growth in the market is likely to be driven by novel treatments and increased 
use of targeted therapies.
Technology and Applications
Research has led to the dis...</description><pubDate>Thu, 10 Feb 2011 04:49:41 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/6437</guid></item><item><title>Practical Oxygen Therapy DVD - a training tool</title><caseId>EXT-10-013</caseId><link>http://hscinnovations.technologypublisher.com/technology/6111</link><description><![CDATA[

The Regional Respiratory Centre in Belfast Health and 
Social Care Trust identified the need for an easily accessible regional specific 
information tool on oxygen therapy.&nbsp; This has resulted in the development 
of a new oxygen therapy information package called O24U designed for the busy 
healthcare professional.
HSC Innovations worked closely with Marion Doherty 
(Staff Nurse) and Dr Jacqui Gamble (Sister) in the Regional Respiratory Centre, 
based in Belfast City Hospital, in marketing the O24U package.&nbsp; As a result 
of this we have now secured the financial support of BOC Healt...]]></description><pubDate>Wed, 05 Jan 2011 02:11:23 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/6111</guid></item><item><title>A Novel Drug Delivery Putty for Topical Applications</title><caseId>EXT-10-009</caseId><link>http://hscinnovations.technologypublisher.com/technology/5299</link><description><![CDATA[This technology is available for 
licensing and partnerships to enable further development and commercialization 
to address a number of unmet medical needs. The lead application is 
administration of an anaesthetic to numb wounds and lacerations without 
injections prior to suturing.
&nbsp;
A proprietary hydrogel-based drug 
delivery platform has been developed that can be used to present a wide range of 
pharmaceutical agents to wound sites such as local anaesthetics, antibiotics and 
wound repair agents.&nbsp; The material 
is applied in the form of a viscous liquid that subsequently self-l...]]></description><pubDate>Wed, 09 Jun 2010 01:22:02 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/5299</guid></item><item><title>Electronic Pharmacist Intervention Clinical System (epics)</title><caseId>EXT-10-015</caseId><link>http://hscinnovations.technologypublisher.com/technology/5250</link><description>
Overview 
The Electronic Pharmacist Intervention Clinical System (epics) 
supports pharmacists in providing an improved and safer quality of care. 
The system records and streamlines many kinds of pharmacy 
activity in order to improve the efficiency and accuracy of the service. 
The portable system provides wirelessly connected handheld 
computers that can be used by clinical pharmacists to access patient and 
pharmacy information around the hospital. 
Patient information is immediately accessible within a secure 
environment at the bedside or in the pharmacy. Pharmacists can record 
interve...</description><pubDate>Fri, 21 May 2010 02:40:33 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/5250</guid></item><item><title>Test for Predicting the Risk of Renal Failure</title><caseId>EXT-10-011</caseId><link>http://hscinnovations.technologypublisher.com/technology/5246</link><description>
Overview 

It is commonly known that patients 
suffering physical trauma (for example caused by planned surgical lesions or 
procedures or unplanned accidents, such as car crashes) may develop acute renal 
dysfunction. 
A challenge faced by physicians is the 
prediction of which patients will suffer renal dysfunction within a time-frame 
that will allow preventative measures to be taken. Routinely-used methods of 
determining renal dysfunction are often too slow and cannot be used to predict 
which patients are at risk, making prevention and treatment of this dangerous 
complication impossibl...</description><pubDate>Fri, 21 May 2010 02:40:30 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/5246</guid></item><item><title>Meningitis Diagnostic</title><caseId>EXT-10-010</caseId><link>http://hscinnovations.technologypublisher.com/technology/5245</link><description><![CDATA[
A RAPID MOLECULAR TEST FOR DETECTION OF NEISSERIA MENINGITIDIS 

Overview 
The pathogenic bacterium Neisseria meningitidis (NMG) is a major worldwide cause of invasive bacterial meningitis and septicaemia, known as meningococcal disease (MD). MD has a average mortality rate of ~10%, largely because of delayed diagnosis and treatment, and survivors are often permanently disabled. Vaccination has reduced the incidence of MD, but no effective vaccine is available for Group B NMG, which causes &gt;40% of UK cases. 
Slow tests to detect NMG are used as a confirmation and mean that the diagnosis cu...]]></description><pubDate>Fri, 21 May 2010 02:40:29 GMT</pubDate><author>enquiries@innovations.hscni.net</author><guid>http://hscinnovations.technologypublisher.com/technology/5245</guid></item></channel></rss>